Also stated was that CGNC was in the early stages of Application for registration. If you have read the company's newsletters you would know that this equates to pre-clinical testing stage. Although the Prof went off and did his own tests, but i presume they of the same stage too...Probably expect an ann. regarding these while he's over maybe??
Of course the Co needs to carry out further trails. If CGNC results are as clinically significant/positive as Roprens were in Phase II's then I could see it being fast tracked in Russia as well. Phase III definitely needed for Western market Approval, as are all drugs.
Not sure why we need to "be careful" when SLA simply have a product that shows enough promise that the head of the Pasture Institute comes all the way over here...
If CGNC is as good as SLA and independent, esteemed Medical Institutions think it is then it has the definite potential to be as big, or bigger than Ropren. But then, the Co has always said that. Just another example of them backing up statements with developements.
But, be careful!!! ;)
Cheers
BB
- Forums
- ASX - By Stock
- SLA
- helens old story
helens old story, page-10
-
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online